Floatz Rating
B56/100
Confidence
Indicative
Sponsor
CanariaBio Inc.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05605535CT.gov Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04498117CT.gov Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oregovamab (this asset) | CanariaBio Inc. | P3 | B · 56 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Olaparib | Institute of Cancer Research, United Kingdom | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Letrozole | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Avutometinib | Verastem, Inc. | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P2/3 | BB |
| Cis-Diamminedichloroplatinum Ii | Genelux Corporation | P3 | BB |
+42 more in the Ovarian Serous Adenocarcinoma cohort
Other indications for Oregovamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Neoplasm | — | P3 | B · 56 |
| Peritoneal Carcinoma | — | P3 | B · 56 |
| Ovarian Carcinoma | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oregovamab in Ovarian Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-ca125-carbohydrate-antigen-mouse-monoclonal-b4313gamma1-chain-disulphide-with-mouse-monoclonal-b4313kappa-chain-dimer-ovarian-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →